- Rheonix to Showcase Automated Molecular Diagnostics Technology at AACC Annual Meeting
Product News: Rheonix to Showcase Automated Molecular Diagnostics Technology at AACC Annual MeetingRheonix Inc., a developer of fully automated molecular testing solutions, will address the need for access to critical advanced molecular testing, labor shortages that limit the availability of testing, and other obstacles laboratories face in adopting this technology at the American Association for Clinical Chemistry (AACC) Annual Meeting in Chicago, Illinois, July 27-31.
Rheonix will display its Chemical and Reagent Device (CARD) and EncompassMDx™ molecular testing platform. The Rheonix CARD® is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention. Once a raw sample is placed on the CARD, the automated EncompassMDx platform runs through the process of sample extraction, DNA purification, amplification and detection. The sample-to-result solution eliminates the need for multiple pieces of existing equipment, helping to make the testing process quicker, more efficient, less expensive and less likely to result in human error.
Held at McCormick Place, the 2014 AACC Annual Meeting will connect leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translation medicine, lab management and other areas of breaking science in laboratory medicine. Participating companies will introduce over 200 new cutting-edge technologies, and offer a wide range of lectures that are designed to inform about changes in the field and vital research. Show attendees are invited to stop by booth 1009 to talk to the Rheonix team and learn more about the company’s technology.
Rheonix recently received funding from the National Institutes of Health to simplify HIV testing. The six-month Phase I award from the NIH is for $189,646, and it is expected to be followed by an 18-month Phase II award of approximately $1.5 million. This follow-on funding is in addition to the $30 million raised in late 2013, in a combination of debt and equity investments led by Rand Capital SBIC Inc., a subsidiary of Rand Capital Corp. (Nasdaq: RAND) and Cayuga Venture Fund.
Image Caption: The EncompassMDx™ molecular testing platform